Form Type:  8-K
Filing Date:  6/12/2013 
CIK:  0001446847 
Address:  301 BINNEY STREET 
City, State, Zip:  CAMBRIDGE, Massachusetts 02142 
Telephone:  617-621-7722 
Last Trade
Last Trade: 
0.02 (0.14%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
Description of Business
We are an entrepreneurial pharmaceutical company focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our team to passionately pursue excellence. If we do these things well, we hope to earn the right to continue doing them and, one step at a time, build an enduring pharmaceutical company that helps patients lead better lives. Our core strategy is to establish a leading gastrointestinal, or GI, therapeutics company, leveraging our development and commercial capabilities in addressing GI disorders as well as our pharmacologic expertise in guanylate cyclase, or GC, pathways. This expertise is based on our work advancing our lead product, linaclotide, which is the first, and to date, only product approved by the U.S. Food and Drug Administration, or FDA, in a new class of GI medicines called guanylate cyclase type-C, or GC-C, agonists.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
      Item 1.01. Entry into a Material Definitive Agreement.